In accordance with our recent study [21], DIO1 expression resulted also in suppression of TGFBI, and several other proteins (e.g. PODXL, CD74) that promote RCC progression [63–65] or act as oncogenic proteins in other cancers (e.g. FMNL2 [66], APBB1IP [67], ASAP1 [68,69], and LRRFIP1 [70,71]). The gene discussed is FMNL2; the disease is renal cell carcinoma.